Recent developments in hepatitis C antiviral research 1999 - 2000

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 8, 2000, Pages 1201-1220

  Reding, M T ^a  

^a PFIZER INC   (United States)

Author keywords

Antisense oligonucleotides; CD81 receptor; DNA vaccines; Helicase; IFN sensitivity determining region; IFN ; Internal ribosome entry site; Non structural proteins; Protease; Ribavirin; Ribozymes; RNA dependent RNA polymerase; Subgenomic replicons

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMANTADINE; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; BUTENOLIDE; CD81 ANTIGEN; CORE PROTEIN; DNA VACCINE; ENZYME INHIBITOR; FOMIVIRSEN; HELICASE; HEPATITIS C VACCINE; HEPTAZYME; HYBRID PROTEIN; IMIDAZOLE DERIVATIVE; INDOMETACIN; LEFLUNOMIDE; LIVE VACCINE; MERIMEPODIB; NORVALINE; NUCLEOSIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; SCH 351633; SODIUM SELENITE; STRUCTURAL PROTEIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; VIRUS RNA; VP 50406;

5' UNTRANSLATED REGION; ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; GENE TARGETING; HEPATITIS C; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; MOUSE; NONHUMAN; PATENT; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; RNA REPLICATION; VIRUS ATTENUATION; VIRUS GENE; VIRUS INHIBITION;

EID: 0033884764     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.8.1201     Document Type: Review

References (124)

1. Development in hepatitis C during 1997-1999
2. Hepatitis C
3. Hepatitis C virus: An overview of current approaches and progress
4. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
5. Overview of hepatitis C virus genome structure. Polyprotein processing and protein properties
6. Internal ribosome entry site-mediated translation in hepatitis C virus replication
7. Processing and functions of hepatitis C virus proteins
8. Candidate targets for hepatitis C virus-specific antiviral therapy
9. Future options for the management of hepatitis C
10. Hepatitis C - Virology and future antiviral targets
11. Hepatitis C virus: Current understanding and prospects for future therapies
12. Hepatitis C virus genome organization and expression: Potential antiviral targets
13. Molecular targets in inhibition of hepatitis C virus replication
14. Molecular virology of hepatitis C virus: An update with respect to potential antiviral targets
15. Targets for inhibition of hepatitis C virus replication
16. A genomic approach of the hepatitis C virus generates a protein interaction map
17. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo
18. Standards of treatment in chronic hepatitis C
19. Interferon-α-2a
20. Problems in the treatment of hepatitis C with interferon
21. Strategies and prospects for vaccination against the hepatitis C viruses
22. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
23. Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development
24. Broadly cross-reactive, high-affinity antibody to the hypervariable region of the hepatitis C virus in rabbits
25. Artificial NS4 mosaic antigen of hepatitis C virus
26. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees
27. DNA vaccines
28. DNA vaccines
29. DNA vaccine strategies for hepatitis C
30. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization
31. A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-alpha promoter elicits HCV-specific cytotoxic T-lymphocytes (CTL)
32. Induction of cytotoxic T lymphocyte response against the core and NS3 genes of the hepatitis C virus in Balb/c mice
33. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization
34. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations
35. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination
36. Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization
37. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model
38. Binding of Hepatitis C virus to CD81
39. Influence of correct secondary and tertiary RNA folding on the binding of cellular factors to the HCV IRES
40. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
41. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation
42. Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression
43. Inhibition of translation of hepatitis C virus RNA by 2'-modified antisense nucleotides
44. Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease
45. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
46. Structural analysis of viral RNA fragments and their recognition by small molecule ligands
47. The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold
48. 2+ to mediate potent, specific inhibition of serine proteases
49. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase
50. Recent progress on NS3 protease as an HCV drug target
51. Hepatitis C virus NS3/4A protease
52. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
53. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A copeptide
54. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase
55. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism
56. Engineering and chemical synthesis of a transmembrane protein: The HCV protease cofactor protein N24A
57. Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide
58. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modeling studies
59. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain
60. Protease inhibitors: Current status and future prospects
61. An uniquely purified HCV NS3 protease and NS4A21-34 peptide form a highly active serine protease complex in peptide hydrolysis
62. A continuous spectrophotometric assay for the hepatitis C virus serine protease
63. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase
64. Effect correction
65. A high-throughput radiometric assay for hepatitis C virus NS3 protease
66. Isolation and structure of SCH 351633: A novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicllium griseofulvum
67. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase
68. Inhibition of the hepatitis C Virus NS3/4A protease
69. α-Ketoacids are potent slow binding inhibitors of the hepatitis C virus protease
70. Synthesis of two novel diphenyl ether analogs of an inhibitor of HCV NS3 protease
71. A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody
72. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein
73. Structure and function of hepatitis C virus NS3 helicase
74. Structure-based mutagenesis study of hepatitis C virus NS3 helicase
75. Structure of the hepatitis C virus RNA helicase domain
76. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding
77. Strand-separating activity of hepatitis C virus helicase in the absence of ATP
78. Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus
79. Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein
80. Probing the relationship between RNA-stimulated ATPase and helicase activities of HCV NS3 using 2'-O-methyl RNA substrates
81. Kinetic analysis of the effects of mutagenesis of W501 and V432 of the hepatitis C virus NS3 helicase domain on ATPase and strand-separating activity
82. The helicase from hepatitis C virus is active as an oligomer
83. DNA binding mediated conformational changes and metal ion coordination in the active site of PcrA helicase
84. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex
85. Hepatitis C virus non-structural 5A protein as a therapeutic target
86. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection
87. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?
88. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
89. Long-term response to interferon alpha is unrelated to 'interferon sensitivity determining region' variability in patients with chronic hepatitis C virus-1B infection
90. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A and NS4B
91. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B and NS5A encoded on the same polyprotein
92. Hepatitis C virus NS5A protein is phosphorylated by casein kinase II
93. Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321
94. Evading the interferon response: Hepatitis C virus and the interferon-induced protein kinase, PKR
95. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon
96. Expression of hepatitis C virus NS5B protein: Characterization of its RNA polymerase activity and RNA binding
97. Hepatitis C virus RNA-dependent RNA polymerase (NS5B polymerase)
98. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region
99. Characterization of suluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli
100. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C reveals a fully encircled active site
101. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
102. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
103. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus
104. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase
105. Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA
106. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein
107. Identification of a cellular protein interacting with RNA polymerase of hepatitis C virus
108. Interferon alfacon-1: A novel interferon for the treatment of chronic hepatitis C
109. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C
110. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
111. Ribavirin polarizes human T cell responses towards a Type I cytokine profile
112. Broadspectrum antiviral antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstrations of antivral additivity with alpha interferon
113. In vitro effect of amantidine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients
114. Amantadine and rimantidine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase and internal ribosomal entry site-mediated translation
115. Interferon/antioxidant combination therapy for chronic hepatitis C - A controlled pilot trial
116. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phophorylation
117. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
118. Zadaxin (thymosin alpha 1) for the treatment of viral hepatitis
119. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C
120. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus
121. α-Glucosidase inhibitors as potential broad based anti-viral agents
122. Cell-based and animal models for hepatitis B and C viruses
123. Systems to culture hepatitis C virus
124. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line